EDITOR:
Cardiac specific troponins were shown to be a powerful independent predictor of future cardiac events in patients suffering from coronary artery disease (CAD) [1] . This disease comprises a wide spectrum of conditions ranging from chronic stable angina to acute myocardial infarction. In CAD patients undergoing major non-cardiac surgery the immediate preoperative period may be associated with silent unstable angina, as suggested by the occurrence of ST segment depression, indicating the development of an ischaemic episode [2] . Consequently, we postulated that an abnormal preoperative troponin plasma level might help identifying patients at very high risk for postoperative coronary complications. This prospective study determined whether abnormal serum cardiac troponin I (cTnI) concentration is associated with an increased risk for postoperative coronary complication in CAD patients undergoing non-cardiac surgery.
After approval from the Institutional Ethics Committee, we performed a prospective study during a 1-yr period in a single hospital (CHU Montpellier). We studied 71 consecutive and informed patients suffering from documented CAD undergoing elective major abdominal surgery. The presence of CAD was defined by at least one of the following criteria: history of typical angina pectoris, past history of myocardial infarction or Q-wave electrocardiographic (ECG) evidence of myocardial infarction, positive exercise ECG or stress echocardiography, preoperative dipyridamidole thallium defect, angiographically proven coronary artery stenosis (Ͼ50%), previous coronary artery bypass surgery or percutaneous coronary angioplasty. Patients with patent unstable angina or recent myocardial infarct (less than 1 month) were excluded. Before operation, a consultant cardiologist clinically evaluated patients. Oral premedication with hydroxyzine was systematically associated with usual cardiac treatment, especially beta-adrenergic blocker, except inhibitors of the renin-angiotensin system which were withdrawn the eve of surgery. Aspirin and other antiplatelet agents were discontinued 8-10 days before surgery and patients received low molecular weight heparin injections. Anaesthesia was left at the discretion of the anaesthesiologist in charge of the patient. Perioperative ST segment analysis was continuously and automatically recorded in leads II, V4 and V5. ST segment deviations were considered as significant when there was a reversible ST segment shift from baseline of у1 mm depression (planar or downsloping), measured 60 ms after the J-point, or у1 mm increase at the J-point, and lasting for at least 1 min. Significant ST segment changes were treated either by correction of the haemodynamic variations or the haematocrit (Ͼ28%) when required, or by an anti-ischaemic therapy (diltiazem, nitroglycerin or beta-adrenergic blocker drug) when the ST segment change persisted. The preoperative coronary treatment of the patient was resumed postoperatively. Postoperative analgesia was ensured by intravenous morphine or epidural patient-controlled administration or intermittent subcutaneous morphine injections. ECG was recorded 1 day before surgery, at arrival in the post-anaesthesia care unit and daily during 3 days and at day 7. Blood samples were obtained for plasma measurement of cTnI the evening before surgery, and at postoperative days 1 and 3. Serum cTnI concentration was measured using the ACCESS ® Troponin I Immunoassay of Sanofi Diagnostics Pasteur, France. The ACCESS ® Troponin I Immunoassay is a double-monoclonal immunoenzymometric assay for quantitative determination of cTnI using magnetic separation and chemoluminescence detection. The analytical range of this test is 0.03-50.0 ng mL Ϫ1 and the cut-off value considered as abnormal is 0.1 ng mL
Ϫ1
. A value higher than 0.15 ng mL Ϫ1 indicates myocardial necrosis [3] . Cardiac complications were defined as the occurrence of myocardial infarction defined as a serum cTnI concentration у0.15 ng mL Ϫ1 associated with permanent new ST segment depression changes or dysrhythmic episode or an acute left ventricular failure. Data were expressed in mean Ϯ SD or number of patients and analysed with the 2 and Fisher's exact tests. One patient having a preoperative value of cTnI higher than 0.15 ng mL
, above the myocardial necrosis threshold [3] was unfit for surgery and sent to a cardiology intensive care unit (ICU). A coronary angioplasty was performed 24 h later. A preoperative serum cTnI concentration between 0.1 and 0.15 ng mL Ϫ1 was noted in five patients. All these five patients with preoperative serum cTnI concentration higher than 0.1 ng mL Ϫ1 experienced a postoperative complication: three experienced a postoperative myocardial infarction (cTnI and ECG changes) with two cardiac-related deaths (40%), one had postoperative peritonitis and one had septic shock requiring infusion of high norepinephrine doses. A postoperative myocardial infarction was noted in 11 among the 65 patients with preoperative cTnI value lower than 0.1 ng mL Ϫ1 : cTnI and ECG changes (8 patients), cTnI and atrial fibrillation (2 patients), cTnI and death from left ventricular failure (1 patient). Postoperative septic shock syndrome occured in four patients having postoperative cTnI measurements greater than 0.15 ng mL Ϫ1 without evidence of myocardial ischaemia. Patients with and without elevated preoperative cTnI (Ͼ0.1 ng mL
) value were similar with respect to patient characteristics (Table 1) . However the incidence of cardiac complication was significantly higher in patients with abnormal i.e. greater than 0.1 ng mL Ϫ1 preoperative cTnI (60% vs. 17%, P ϭ 0.001).
Major efforts in patients with CAD undergoing non-cardiac surgery are directed towards identifying patients at high risk of postoperative adverse outcome and subsequently to institute measures to improve the prognosis. This study shows that in patient with patent CAD scheduled for elective major abdominal surgery a preoperative abnormal troponin serum concentration before surgery is associated with a very high risk for postoperative life threatening cardiac complication. In the immediate preoperative period, several factors may provoke unstable angina in patients with chronic stable CAD, a critical phase of the disease which may be silent. These factors include the preoperative emotional stress and cessation of antiplatelet agent [4] . The superiority of cardiac specific troponins over the ECG to predict future cardiac events in patients with unstable angina has been confirmed by both prospective and retrospective analysis. Troponin may seem to be a surrogate marker for unstable atherosclerotic plaques and consequent microembolization causing myocardial damage. Myocardial cell injury before necrosis can be accurately detected by elevated values of cardiac troponin in the circulation during unstable angina [5] . Furthermore, a slight elevation of troponin plasma level is an accurate indicator for unstable coronary states, which could be silent, and represents a reliable predictor of early high-risk patients [6] . These observations lead us to add the measurement of these markers in the immediate preoperative period in patients suffering from patent CAD.
In this study, an abnormal serum troponin concentration, even a very slight increase with a serum concentration lower than 0.15 ng mL
, which may reveal a critical phase of the ischaemic heart disease, indicated a very high incidence of postoperative complications. These observations provide additional impetus for considering the measurements of these markers in the immediate preoperative period which may help detecting patients at very high risk who The involvement of nitric oxide on the analgesic effect of tramadol
EDITOR:
Tramadol is a synthetic centrally acting analgesic drug with opioid agonist activity selectively on µ receptors and weakly on and receptors. It also inhibits reuptake of norepinephrine and increases extraneuronal serotonin concentrations. Nitric oxide (NO), produced from L-arginine by the enzyme nitric oxide synthase (NOS) increases the intracellular content of cyclic GMP. The activation of the L-arginine-NO-c-GMP pathway is involved in the modulation of pain perception and in the nociceptive transmission at spinal and supraspinal levels [1] . N G -nitro-L-arginine methyl ester (L-NAME) is a non-selective antagonist that inhibits the activity of both endothelial NOS (eNOS) and neuronal NOS (nNOS), while 7-nitro indazole (7-NI) has been described as a nNOS inhibitor in vivo [2] . The role of NOS inhibitors on the systemic analgesic effect of tramadol has not been studied previously. We aimed to investigate the interaction of NOS inhibitors L-NAME and 7-NI with tramadol by using thermal and chemical pain models.
After local animal Ethics Committee approval, 108 adult female Swiss-Webster mice 25-45 g served as the subjects. Hot-plate and acetic acid induced writhing tests were used in order to assess nociception. All drugs were injected intraperitoneally, in a volume of 10 mL kg
Ϫ1
, by the same person and from the same side. Control animals received saline, 36 mice were randomly assigned into six equal groups for the hotplate test. The first injection was saline, L-NAME 10 mg kg Ϫ1 or 7-NI 3 mg kg
. Twenty minutes after the first intraperitoneal injection, the mice received either saline or Tramadol 40 mg kg
. Each mouse was placed on a hot-plate, at 55°C 20 min after the second injection. A cut off latency period of 40 s was used in order to prevent tissue damage. Measurements were repeated at the 50th and 80th minutes of injection.
Seventy-two mice were randomly allocated into three groups to receive intraperitoneal saline, L-NAME 10 mg kg Ϫ1 , or 7-NI 3 mg kg
. Each main group was divided into four subgroups to make 12 groups. Twenty minutes after the first injection another injection of saline, tramadol 10 mg kg Ϫ1 , tramadol 20 mg kg
, tramadol 40 mg kg Ϫ1 were applied to the subgroups of these three main groups. Writhing was induced by an intraperitoneal injection of 3% acetic acid at a dose of 300 mg kg Ϫ1 20 min after the second injections. The number of writhes per animal was counted during a 15 min test period, starting at the 5th minute after injection of acetic acid. Constriction of abdomen, turning of trunk to one side, and extension of hind legs were accepted as one writhing. Friedman test was used for analysing time effect in hot-plate latencies. Kruskal-Wallis test was used for comparing groups and U-test was used with correction of significance for post-hoc multiple comparisons. P Ͻ 0.05 values were accepted as statistically significant (Fig. 1) .
Although 7-NI did not show any increase in hotplate latencies by itself, it increased the analgesic effect of tramadol significantly in the hot-plate tests performed at the 20th and the 50th minutes after injections. 7-NI pretreatment lead to significantly longer hot-plate latencies compared to tramadol alone, the effect was emphasized in the 50th minute after injections. L-NAME pretreatment followed by tramadol administration did not show a significant change in hot-plate latencies compared to tramadol alone. 7-NI or L-NAME pretreatments did not possess an analgesic effect solely on writhing tests (Table 1) . No statistically significant differences were observed when the pretreatments were compared in the three doses of tramadol used in the study.
Systemic pretreatment with 7-NI, augmented the analgesic effect of tramadol in the hot-plate test in mice. The same dose of 7-NI itself administered alone, demonstrated no analgesic effect on its own. In contrast to systemic interaction of tramadol with 7-NI in hot-plate test, no interaction between tramadol and L-NAME in both hot-plate and acetic acid induced writhing was observed. 7-NI increased the analgesic effect of tramadol in thermal pain model, not in acetic acid induced writhing test.
L-NAME pretreatment did not increase the analgesic effect of tramadol both in hot-plate and acetic acid induced writhing tests.
Our results emphasize the possible involvement of different mechanisms, other than those that have been identified, taking part in the analgesic effect of tramadol. It has been proposed that some non-steroidal anti-inflammatory drugs stimulate NO production, which results in increased c-GMP levels and antinociception [3] . Inhibition of NOS activity also attenuates ketamine antinociception [4] . NO-c-GMP pathway is also involved in the mechanism of benzodiazepine induced antinociception in the writhing test in mice [2] . On the other hand there are several observations indicating that NO-c-GMP pathway plays a hyperalgesic rather than antinociceptive role [5] .
Neuronal NOS inhibitors, inhibit hyperalgesia in the rat regardless of the type of noxious stimuli [6] . L-NAME has a synergistic antinociceptive interaction with morphine in response to thermal stimulation when given intrathecally, epidurally or intravenously in rats but it inhibits the analgesic effect of ketamine in rats [4] . L-NAME potentiates the antinociception induced by sumatriptan and buspiron but does not alter the pain threshold itself in the acetic acid writhing assay at a dose of 20 mg kg Ϫ1 [7] . In mice, a 94% inhibition of cortical NOS activity has been reported following administration of L-NAME [4] . So we assumed that this used dose in our study would be enough to inhibit the brain NOS activity. We could not find an increase in the analgesic effect of tramadol when the mice were pretreated with L-NAME.
The mechanism of antinociception in the writhing test in mice involves NO-c-GMP pathway [2] . NOS inhibitors fail to alter acute thermal and mechanical pain, whereas persistent chemical pain associated with writhing or the second phase of formalin assay are very sensitive to inhibition by these drugs [2] . Writhing reflects nociception that unlike the tail-flick and hot-plate tests, is mediated by NMDA receptor activity known to be associated with NO synthesis. Writhing assay is somewhat unique as it involves a noxious stimulus and behavioural responses that persist for a sufficient time interval to reflect sensitivity to the relatively slow generation of NO. We found that systemic pretreatment with the NOS inhibitor 7-NI augmented the analgesic effect of tramadol in the hot-plate test even though it did not exhibit an analgesic effect by itself. No effects of pretreatments with 7-NI or L-NAME were observed in acetic acid induced writhing. The potentiation of analgesic effect of tramadol by 7-NI might be an indicator of the involvement of NO in the antinociceptive effect of tramadol. This is a preliminary study which suggests that NOS inhibitors may interfere with the analgesic effect of tramadol for the first time. It is also possible that 7-NI may increase the analgesic effect of tramadol other than the inhibition of neuronal NOS inhibition with some indistinct mechanism. In order to find out the overall aspects of this synergism, further studies are required.
EDITOR:
It has been shown that the semi-recumbent position reduces the risk of aspiration and the incidence of clinically and microbiologically diagnosed ventilator associated pneumonia (VAP). Nevertheless the benefits of this approach in the neurosurgical patient population remain unclear because previous studies evaluating semi-recumbent positioning and its effect on pneumonia development have excluded neurosurgical patients for fear of decreased cerebral perfusion and differences in institutional policies for positioning.
Our audit protocol was designed to test the hypothesis that a raised head-of-bed 30 degree position is safe for euvolemic patients with traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH) regarding changes in intracranial pressure (ICP) and cerebral perfusion pressure (CPP).
Material and methods
With approval of the Ethics Committee of the RWTH Aachen University which granted a waiver for written informed consent, five patients with SAH and five patients with TBI and ICP at baseline around 10 mmHg were studied. ICP and CPP were measured with the transducers calibrated to the level of the foramen of Monro. Continuous cardiac output (CO) and systemic vascular resistance (SVR) were measured with the PiCCO Measurements were only performed whenever routine nursing procedures required position changes anyway and the clinician judged the patient to be euvolemic based on systolic pressure variation or stroke volume variation patterns.
Data were analysed as percentage of change from baseline and given as mean and confidence interval (CI). Wilcoxon signed rank sum tests were performed between groups when appropriate to determine statistical significance.
Results
The patients included in the study had a Glasgow Coma Scale on admission between 3 and 8, and were sedated with midazolam and sufentanil to a Riker score of 2-3 and mechanically ventilated via an endotracheal tube with an ICP of 10 (Ϯ2) mmHg at the time measurements were performed. Table 1 shows the summary of changes between different PEEP levels and position. A significant increase in ICP and reduction in CPP was seen with position change from 30 degrees to flat. Increase in PEEP from 5 to 10 cmH 2 O increased ICP without dropping CPP significantly while further increase of PEEP to 15 cmH 2 O resulted in increased ICP with significant CPP drop. In the 30 degree position a PEEP increase from 5 to 10 cmH 2 O did not lead to significant changes in ICP or CPP (although there was a trend of increased ICP) and further increase to 15 cmH 2 O PEEP resulted in significantly increased ICP but no significant change in CPP.
With 30 degrees head-up tilt there was an overall trend towards a mild reduction in cardiac index and a mild increase in SVR, which never reached statistical significance. Cerebral blood flow (CBF) velocity in all measured vessels was either unchanged or minimally reduced.
End-tidal CO 2 concentrations did not change during the study period.
Discussion
Older studies by Rosner and Coley [1] and March and colleagues [2] raised controversy about the benefits of the elevated head position in patients with increased ICP because of the potential for CPP reduction. This is especially true in patients who are considered to be hypovolaemic secondary to diuretic therapy or osmotic therapy without adequate volume replacement. Our results indicate that head elevation is safe and effective in reducing ICP and optimising CPP and CI if euvolemia is maintained.
A systematic review by Fan [3] in 2004 identified 11 clinical trials related to backrest position, ICP and CPP with nine demonstrating a benefit of head Table 1 . Overview about changes in % from baseline (see footnotes # and ##) given as mean and range. Ϫ2 (Ϫ5 to ϩ3) Ϫ1 (Ϫ4 to ϩ3) 0 (Ϫ6 to ϩ5) 0 (Ϫ2 to ϩ3) Ϫ1 (Ϫ2 to ϩ1) MCA right Ϫ3 (Ϫ5 to ϩ3) 0 (Ϫ3 to ϩ 3) 0 (Ϫ6 to ϩ5) Ϫ1 (Ϫ3 to ϩ3) Ϫ1 (Ϫ2 to ϩ1) ICA left Ϫ4 (Ϫ10 to ϩ5) Ϫ2 (Ϫ5 to ϩ3) Ϫ1 (Ϫ8 to ϩ5) Ϫ1 (Ϫ6 to ϩ5) 0 (Ϫ5 to ϩ4) ICA right Ϫ4 (Ϫ11 to ϩ5) Ϫ3 (Ϫ6 to ϩ3) Ϫ1 (Ϫ8 to ϩ5) Ϫ1 (Ϫ6 to ϩ5) Ϫ1 (Ϫ6 to ϩ4)
